Literature DB >> 18753636

Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells.

Clotilde Simon1, Elisabetta Dondi, Amandine Chaix, Paulo de Sepulveda, Terrance J Kubiseski, Nadine Varin-Blank, Laura Velazquez.   

Abstract

Stem cell factor (SCF) plays critical roles in proliferation, survival, migration, and function of hematopoietic progenitor and mast cells through binding to Kit receptor. Previous studies have implicated the adaptor protein Lnk as an important negative regulator of SCF signaling. However, the molecular mechanism underlying this regulation is unclear. Here, we showed that the Src homology 2 domain (SH2) of Lnk binds directly and preferentially to phosphorylated tyrosine 567 in Kit juxtamembrane domain. Using Lnk(-/-) bone marrow mast cells (BMMCs) transduced with different Lnk proteins, we demonstrated that Lnk down-regulates SCF-induced proliferation with attenuation of mitogen-activated protein kinase (MAPK) and c-jun N-terminal kinase signaling. Furthermore, we showed that Lnk(-/-) BMMCs displayed increased SCF-dependent migration compared with wild-type cells, revealing a novel Lnk-mediated inhibitory function. This correlated with enhanced Rac and p38 MAPK activation. Finally, we found that Lnk domains and carboxy-terminal tyrosine contribute differently to inhibition of in vitro expansion of hematopoietic progenitors. Altogether, our results demonstrate that Lnk, through its binding to Kit tyrosine 567, negatively modulates specific SCF-dependent signaling pathways involved in the proliferation and migration of primary hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753636     DOI: 10.1182/blood-2008-05-154849

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

2.  LNK (SH2B3) is a key regulator of integrin signaling in endothelial cells and targets α-parvin to control cell adhesion and migration.

Authors:  Julie Devallière; Mathias Chatelais; Juliette Fitau; Nathalie Gérard; Philippe Hulin; Laura Velazquez; Christopher E Turner; Béatrice Charreau
Journal:  FASEB J       Date:  2012-03-21       Impact factor: 5.191

3.  The regulation of normal and leukemic hematopoietic stem cells by niches.

Authors:  Meng-Meng Huang; Jiang Zhu
Journal:  Cancer Microenviron       Date:  2012-07-22

Review 4.  The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.

Authors:  N Maslah; B Cassinat; E Verger; J-J Kiladjian; L Velazquez
Journal:  Leukemia       Date:  2017-05-09       Impact factor: 11.528

5.  Genetic loss of SH2B3 in acute lymphoblastic leukemia.

Authors:  Arianne Perez-Garcia; Alberto Ambesi-Impiombato; Michael Hadler; Isaura Rigo; Charles A LeDuc; Kara Kelly; Chaim Jalas; Elisabeth Paietta; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Maddalena Paganin; Giuseppe Basso; Wei Tong; Wendy K Chung; Adolfo A Ferrando
Journal:  Blood       Date:  2013-08-01       Impact factor: 22.113

6.  Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.

Authors:  Sigal Gery; Qi Cao; Saskia Gueller; Hongtao Xing; Ayalew Tefferi; H Phillip Koeffler
Journal:  J Leukoc Biol       Date:  2009-03-17       Impact factor: 4.962

Review 7.  A survival Kit for pancreatic beta cells: stem cell factor and c-Kit receptor tyrosine kinase.

Authors:  Zhi-Chao Feng; Matthew Riopel; Alex Popell; Rennian Wang
Journal:  Diabetologia       Date:  2015-02-03       Impact factor: 10.122

Review 8.  The function of SH2B3 (LNK) in the kidney.

Authors:  Gregory Blass; David L Mattson; Alexander Staruschenko
Journal:  Am J Physiol Renal Physiol       Date:  2016-07-20

9.  SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.

Authors:  Maya Koren-Michowitz; Sigal Gery; Takayuki Tabayashi; Dechen Lin; Rocio Alvarez; Arnon Nagler; H Phillip Koeffler
Journal:  Br J Haematol       Date:  2013-04-17       Impact factor: 6.998

10.  When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms.

Authors:  Stephen T Oh
Journal:  Ther Adv Hematol       Date:  2011-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.